It was a busy week for the biotech sector with a lot of important data readouts at the European Society for Medical Oncology ...

GILD's industry had an average PEG ratio of 2.28 as of yesterday's close. The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 79 ...

A Freemasons Lodge has made a “lasting impact” after donating £1,000 to the 1st Leverington Rainbows group. The donation from ...

Two years ago, a few friends who regularly met at the Speckled Paw in Mt. Gilead formed a group called the Dollar Club. This ...

Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $81.44 which represents a slight increase of $2.27 or 2.87% from the prior close of $79.17. The stock opened at $79.17 and ...

Gilead said Thursday that its twice-yearly antiviral reduced the risk of HIV infections by 96% compared to an expected rate ...

Caprock Group LLC grew its position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 44.1% during the second quarter, according to its most recent 13F filing with the SEC.The ...

Drugmaker Gilead Science announced Thursday that its biannual injections to prevent against HIV had slashed the risk of ...

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...

Gilead Sciences' Phase 3 trial results show twice-yearly HIV-1 capsid inhibitor lenacapavir reduced HIV infections by 96%, ...

Gilead Sciences Inc.’s twice-yearly HIV prevention shot prevented almost all HIV cases in a large trial in men and transgender people, a result that will allow the company to file for approval by end ...

Gilead researchers say lenacapavir “has the potential to be one of the most impactful interventions” in the battle against ...